Revolutionizing Precision Medicine with the Power of AI and Metabolites

Why Metabolites

Metabolites are small molecules like glucose & cholesterol that are produced during metabolic processes.

  • They direct readouts of both genetic & non-genetic factors associated with disease and drug response.
  • Metabolites are secreted to the blood from normal tissues and disease cells.
  • The study of <200 blood metabolites in >117,000 individuals predicted multi-disease outcomes. (Nature Medicine, 28, 2022, 2309–2320)





Our patented technology can characterize 20x more metabolites than any other platform for each patient.


We then use these large-scale metabolomic data to create digital metabolic twins, computer representations of metabolic processes within multi-omic contexts.


How does our technology work?

Precision Oncology


Immuno-oncology

Cancer immunotherapy drugs activate the body's immune system to fight cancer.

They have revolutionized cancer treatment. However:

  • <20% of patients benefit from immunotherapy
  • >35% of patients develop severe immune-related adverse events

Our AI-enabled precision medicine platform tackles all these problems by predicting which patients benefit from immunotherapy.

Precision Oncology


"The Obesity Paradox"

Obese individuals face a higher cancer risk but respond better to immunotherapy.

Cancer is a systematic disease that alters systematic metabolism and blood metabolites.

Our AI-platform detects changes in blood metabolites at unprecedented levels, offering crucial insights into the metabolism of the host, the tumor, and their interplay.

Precision Oncology


RCC metabolic twins

Renal cell carcinoma (RCC) metabolic twins shed light on the immuno-metabolic mechanism associated with disease progression and treatment response.

Our RCC metabolic twins accurately predict which patients will respond to cancer immunotherapy before treatment.

Precision Cardio-metabolic


Metabolic health is currently assessed using oversimplified metrics like BMI, fasting glucose, or limited lipid panels.



We use AI and 10,000+ lipids and metabolites to develop digital metabolic twins.


Our digital metabolic twins predict metabolic health beyond BMI and risk of T2D, CVD, and other chronic diseases.

Partner with us

We believe in the power of partnerships to bring the right treatment for the right patients faster

Pipeline expansion

By utilizing multi-modal metabolomics data, we identify novel biological insights to discover new targets, prioritize them in development, explore indication expansion, and strategize drug combinations.

Optimized clinical trial design

We enhance clinical trial design by developing fine-tuned AI models based on proprietary pre-trained foundation models. These models increase the likelihood of success and decrease the size of clinical trials.

Integration with ctDNA tests

Our metabolomics data and pre-trained foundation models improve patient genetic stratification. We partner with liquid biopsy companies to increase the accuracy of their ctDNA tests by integrating metabolomics data.

Learn more:

TECHNOLOGY

Developed at MIT and published in Nature Methods

ABOUT US

Learn more about our founders and team

NEWS

ReviveMed presented at ASCO 2024

Contact us

ADDRESS:

ReviveMed Inc

245 First St.,

Cambridge, MA, 02142


Follow us on:

ReviveMed Inc. | info@revivemed.io | copyright ©2024